Drug Profile
Padeliporfin - ImPact Biotech
Alternative Names: Padeliporfin di-potassium - ImPact Biotech; Padeliporfin ImPACT; Padeliporfin VTP; Palladium bacteriopheophorbide monolysine taurine; Stakel; TOOKAD Soluble; WST-11Latest Information Update: 22 Dec 2023
Price :
$50
*
At a glance
- Originator Steba Laboratories
- Developer ImPact Biotech
- Class Antineoplastics; Eye disorder therapies; Porphyrins; Small molecules
- Mechanism of Action Photosensitisers; Vascular disrupting agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Prostate cancer
- Phase III Urogenital cancer
- Phase I/II Renal cancer
- Phase I Oesophageal cancer
- Preclinical Degenerative myopia; Pancreatic cancer
- Suspended Choroidal neovascularisation
- No development reported Cholangiocarcinoma; Non-small cell lung cancer
Most Recent Events
- 20 Dec 2023 US FDA approves IND application for Padeliporfin in Pancreatic cancer
- 11 Oct 2023 Adverse events and pharmacodynamics data from a preclinical study in Pancreatic cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
- 02 Oct 2023 Memorial Sloan Kettering Cancer Center completes a phase I trial for Urogenital cancer (Recurrent, Second-line therapy or greater, Inoperable/Unresectable) in USA (IV) (NCT03617003)